OBJECTIVES: Primary - Evaluate the ability of early chemotherapy to improve overall survival of patients commencing androgen deprivation for metastatic prostate cancer. Secondary - Determine whether early chemotherapy can increase the time to clinical progression (radiographic or symptomatic deterioration due to disease) over hormonal therapy alone. - Determine whether early chemotherapy can increase the time to development of hormone-refractory disease over hormonal therapy alone. - Determine whether early chemotherapy can increase the time to serological progression over hormonal therapy alone. - Determine rates of biochemical response at 6 months and 12 months in the chemohormonal arm versus the hormonal therapy alone arm. - Determine the frequency of adverse events and the tolerability of chemotherapy combined with hormonal therapy versus hormonal therapy alone. - Determine whether the postulated clinically meaningful increase in disease control is associated with an alteration in overall quality of life using the Functional Assessment of Cancer Therapy-Prostate questionnaire. - Determine the ability of prostate-specific antigen changes to be a surrogate for clinical benefit from therapy and overall survival. Tertiary - Determine whether there are proteins differentially translated from the genome in hormone-sensitive prostate cancer, prostate cancer that has responded to hormonal therapy, and hormone-refractory prostate cancer. - Determine the frequency of constitutive polymorphisms of enzymes involved in steroid metabolism and other carcinogenic processes. - Determine whether the amount and frequency of certain carcinogenic proteins in prostate cancer tissue such as CXCR4 and manganese superoxide dismutase can be correlated with a poor prognosis. OUTLINE: This is a randomized, multicenter study. Patients are stratified according to age (≥ 70 vs < 70), ECOG performance status (0-1 vs 2), combined androgen blockade for > 30 days (yes vs no), duration of prior adjuvant hormonal therapy (> 12 months vs ≤ 12 months), concurrent bisphosphonate use (yes vs no), and volume of disease (low vs high). Patients are randomized to 1 of 2 treatment arms. - Arm A: Patients receive androgen-deprivation therapy (including luteinizing hormone-releasing hormone [LHRH] agonist therapy, LHRH antagonist therapy, or surgical castration). Patients also receive docetaxel IV over 1 hour on day 1. Treatment with docetaxel repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. - Arm B: Patients receive androgen-deprivation therapy (as in arm A) alone. Quality of life is assessed at baseline and at weeks 12, 24, 36, and 48. After completion of study treatment, patients are followed up periodically for up to 10 years.
Last updated: 12/04/2012